Dual Histone Deacetylase/PD-1/PD-L1 Inhibitors Reprogram Tumor−Immune Interactions and Are Effective in Therapy-Resistant Melanoma
Epigenetic modulators and immune checkpoint inhibitors represent two major therapeutic avenues in oncology, yet resistance and recurrence limit their efficacy. To address this, we designed and synthesized a series of dual histone deacetylase (HDAC)/PD-1/PD-L1 inhibitors (compounds 1−6). Among them, compounds 4 (HDAC6...